Q-omics provides the consensus-scored CABS1 profile across patient tissues and cancer cell-line models. CABS1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CABS1 is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, CABS1 RNA expression shows 6,500 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, and STAD as cancer lineages where CABS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CABS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CABS1 survival associations across molecular data types. CABS1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CABS1 RNA expression–survival associations across cancer types. High CABS1 expression shows unfavorable associations in COAD, KIRC, THYM and DLBC, but favorable associations in BLCA and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for CABS1 RNA expression.
This table summarizes CABS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CABS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CABS1 shows lower tumor expression in BLCA, PRAD and HNSC and higher tumor expression in KIRP and COAD. The BLCA box plot shows higher CABS1 RNA expression in normal versus tumor tissue (log2 FC = −0.103, t-test p = .013).
This table shows molecular features associated with CABS1 in patient tissues and cancer cell lines. In patient samples, CABS1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CABS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
